|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-3-7
|
|
pubmed:abstractText |
In multiple myeloma (MM) YKL-40 is present in the bone marrow microenvironment and is suggested to play a role in remodelling of the extracellular matrix. Here, the association between serum YKL-40 and severity of bone disease in MM is investigated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1600-0609
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
80
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
310-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18182077-Adipokines,
pubmed-meshheading:18182077-Adult,
pubmed-meshheading:18182077-Aged,
pubmed-meshheading:18182077-Aged, 80 and over,
pubmed-meshheading:18182077-Biological Markers,
pubmed-meshheading:18182077-Bone Diseases,
pubmed-meshheading:18182077-Disease Progression,
pubmed-meshheading:18182077-Female,
pubmed-meshheading:18182077-Glycoproteins,
pubmed-meshheading:18182077-Humans,
pubmed-meshheading:18182077-Lectins,
pubmed-meshheading:18182077-Male,
pubmed-meshheading:18182077-Middle Aged,
pubmed-meshheading:18182077-Multiple Myeloma,
pubmed-meshheading:18182077-Serum,
pubmed-meshheading:18182077-Survival Rate
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients.
|
|
pubmed:affiliation |
Department of Haematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. anne.k.mylin@dadlnet.dk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
